Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Sees Unusually-High Trading Volume – Still a Buy?

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) saw strong trading volume on Monday . Approximately 2,413,917 shares traded hands during trading, an increase of 94% from the previous session’s volume of 1,244,418 shares.The stock last traded at $14.2135 and had previously closed at $14.44.

Analysts Set New Price Targets

Several analysts have recently issued reports on the stock. Deutsche Bank Aktiengesellschaft raised shares of Bayer Aktiengesellschaft from a “hold” rating to a “buy” rating in a research note on Thursday, July 2nd. DZ Bank raised Bayer Aktiengesellschaft from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, May 19th. Zacks Research upgraded Bayer Aktiengesellschaft from a “hold” rating to a “strong-buy” rating in a research note on Friday, July 10th. Finally, Jefferies Financial Group raised Bayer Aktiengesellschaft to a “hold” rating in a research note on Friday, May 29th. Two analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating and one has assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Buy”.

Bayer Aktiengesellschaft Trading Down 1.7%

The business’s 50-day moving average is $12.64 and its two-hundred day moving average is $12.13. The company has a current ratio of 1.05, a quick ratio of 0.70 and a debt-to-equity ratio of 1.06. The stock has a market capitalization of $55.79 billion, a PE ratio of -27.83, a PEG ratio of 4.52 and a beta of 0.55.

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) last issued its earnings results on Tuesday, August 4th. The company reported $0.29 earnings per share for the quarter, topping the consensus estimate of $0.23 by $0.06. The company had revenue of $12.53 billion during the quarter, compared to the consensus estimate of $12.31 billion. Bayer Aktiengesellschaft had a positive return on equity of 17.00% and a negative net margin of 3.80%.Bayer Aktiengesellschaft has set its FY 2026 guidance at 1.200-1.346 EPS. On average, analysts predict that Bayer Aktiengesellschaft will post 1.28 earnings per share for the current year.

Bayer Aktiengesellschaft Company Profile

Bayer Aktiengesellschaft is a global life sciences company headquartered in Leverkusen, Germany, with a history dating back to 1863. The company operates across three principal business areas—Pharmaceuticals, Consumer Health and Crop Science—serving customers and markets worldwide. Bayer develops, manufactures and markets prescription medicines, over-the-counter healthcare products and agricultural solutions, and maintains research and development programs focused on new therapies and technologies in its core fields.

In Pharmaceuticals, Bayer focuses on prescription drugs across therapeutic areas such as cardiology, oncology, hematology and women’s health, supporting clinical development and regulatory activities for both marketed products and pipeline candidates.